Twist Bioscience Corp vs VF Corp — how do they compare? Twist Bioscience Corp trades at $161.23 (market cap $10.08B), while VF Corp trades at $14.87 (market cap $5.71B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and VF Corp pays a 2.48% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and VF Corp for 64 Days on average.
| TWST | VFC | |
|---|---|---|
Market Cap | $10.08B | $5.71B |
Volume | 4,229,037 | 8,987,330 |
Sector | Health | Consumer Cyclical |
52-Week High | $205.00 | $21.55 |
52-Week Low | $25.45 | $12.62 |
Typical Hold Time | 27 Days | 64 Days |
Enterprise Value | $10.01B | $10.00B |
Dividend Yield | — | 2.48% |
Signals from Pluang's Aura AI — not financial advice
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
VFC trades at $14.38, down 0.48% with a bullish technical signal from moving averages. The company shows mixed fundamentals with revenue declining from $11.8B in 2022 to $9.5B in 2025, while profitability remains challenged with negative net income of -$189.72M. Recent earnings show volatility with one beat and two misses in the last four quarters. The stock trades at attractive valuation multiples with P/E of 21.06 and P/S of 0.61, below industry averages.
VFC presents a turnaround opportunity with discounted valuation and improving cash flow projections for 2026, but faces significant execution risks from Vans brand weakness and ongoing debt reduction challenges. Analyst consensus leans neutral with 52% hold rating and $18.33 price target suggesting 27% upside potential, though recent dividend cuts and brand-specific headwinds require careful monitoring of Q3 earnings performance.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →